Bill of Health

OCTOBER 31, 2022

Some COVID-19 vaccine manufacturers in the US have refused to share vaccine samples for research purposes , creating an access issue with the potential to delay comparator studies, follow-on research, and new vaccine / drug development. By Aparajita Lath. However, some suggest that patents are impeding access to research. 3d 1351 (Fed.

COVID-19 167

COVID-19 COVID-19 Vaccine Licensing FDA 167

SQA

SEPTEMBER 2, 2022

ANVISA published the RDC 702/2022, which repeals some requirements that were instituted to speed market approval of devices needed to treat patients during the height of the COVID-19 pandemic. The Regulations were first issued with immediate effect in 2002 and were later revised in 2016.

FDA 91

FDA COVID-19 Nursing Homes Compliance 91

SQA

DECEMBER 16, 2022

19 Medical Rehabilitation Equipment. It will also facilitate cross-border circulation of these critical health therapies as well as cross-border cooperation between public health authorities. This proposal builds upon the existing legal framework, which came into force in 2002 for blood and 2004 for tissues and cells.

FDA 40

FDA Compliance COVID-19 Licensing 40

SQA

FEBRUARY 26, 2024

These are requirements of the Therapeutic Goods (Medical Devices) Regulations 2002. The MDVP pilot aims to identify areas that may require improvement in order to ensure appropriate monitoring and communications are in place to support the ongoing safety of medical devices available to the Australian public.

FDA 52

FDA Compliance COVID-19 Public Health 52

Drug & Device Law

JANUARY 4, 2024

So we do have comments on the bizarre complaint that the Texas attorney general recently filed over COVID-19. The complaint, brought under the Texas consumer protection statute, sued a major manufacturer of COVID-19 vaccine that was used to control the recent pandemic. 2002); Tracker Marine, L.P. 3d 675, 698 (Tex.

COVID-19 Vaccine 59

COVID-19 Vaccine COVID-19 FDA Public Health 59